What type of study is this?

This is a Human Clinical Trial study (also classified as: Pre-Registered Trial).

What question did this study set out to answer?

To evaluate the differences in overall survival and quality of life for MDS patients treated with azacytidine vs decitabine.

December 8, 2025Blood

View Full Paper

Ask AI

Bookmark

To evaluate the differences in overall survival and quality of life for MDS patients treated with azacytidine vs decitabine.
Retrospective cohort study using data from the Canadian MDS Registry
Patients with MDS treated with azacytidine or decitabine were included
Primary outcome was overall survival compared using log-rank test
Secondary outcomes included Leukemia-Free Survival and quality of life measurements
Propensity-score matching analysis conducted on treatment groups based on IPSS-R and frailty score
No significant difference in overall survival between azacytidine and decitabine (34.4 vs. 21.1 months)
Patients treated with azacytidine received more cycles of therapy compared to decitabine
QoL measures showed stability with no significant difference between treatment groups
Increased dyspnea and fatigue scores observed in decitabine treated patients over time
Higher-risk MDS patients may experience a survival benefit with decitabine.

Authors

No takes yet. Share an insight, caveat, or question.

Propensity matched analysis reveals no survival difference between azacytidine and decitabine in MDS patients, suggesting similar clinical outcomes.

England et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Propensity matched analysis reveals no survival difference between azacytidine and decitabine in MDS patients, suggesting similar clinical outcomes.